This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is QIAGEN N.V. (QGEN) Stock Outpacing Its Medical Peers This Year?
by Zacks Equity Research
Is (QGEN) Outperforming Other Medical Stocks This Year?
Boston Scientific's Eluvia Gets CMS' Additional Reimbursement
by Zacks Equity Research
Boston Scientific (BSX) gains CMS' NTAP designation for its Eluvia stent system, thus providing additional reimbursement to Medicare beneficiaries suffering from PAD.
Why Is Qiagen (QGEN) Up 7.5% Since Last Earnings Report?
by Zacks Equity Research
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medicare Coverage for Libre 2 Boosts Abbott's CGM Prospects
by Zacks Equity Research
Abbott's (ABT) FreeStyle Libre 2 iCGM is now available to Medicare-eligible diabetic patients via CMS' reimbursement expansion.
Athenex's NDA for Breast Cancer Drug Gets Priority Review
by Zacks Equity Research
The FDA accepts Athenex's (ATNX) NDA for oral paclitaxel and encequidar, intended to treat metastatic breast cancer, under a priority review. The FDA's verdict is awaited on Feb 28, 2021. Stock up.
Bristol Myers Gets FDA Approval for Oral AML Therapy Onureg
by Zacks Equity Research
Bristol Myers' (BMY) Onureg becomes the first and only FDA-approved continued AML therapy for patients in remission.
Medtronic (MDT) Plans Up to $475M of Annual Cost Savings
by Zacks Equity Research
Medtronic (MDT) expects its new operating model to help it become more focused in terms of speeding up research and developments.
ResMed (RMD) Launches First CPAP Nasal Mask With Memory Foam
by Zacks Equity Research
ResMed (RMD) adds another product to its line of easy-to-use, convenient and comfortable masks.
Aimmune Set to be Acquired by Nestle for $2.6B, Stock Up
by Zacks Equity Research
Aimmune (AIMT) reaches an agreement with Nestle, S.A wherein the latter will acquire the company in an all-cash transaction worth $2.6 billion. Shares surge.
Phirbo's Product Mix Aids, Global Animal Health Business Ails
by Zacks Equity Research
Phirbo (PAHC) catered industries face issues like lack of processing availability and sudden drop in demand.
Medtronic's Pediatric Diabetes Device Gets Regulatory Nod
by Zacks Equity Research
MiniMed 770G is Medtronic's (MDT) MiniMed 670G System's upgraded version.
OMRI Clears NEOGEN's AquaPrime Peraside 15 as USDA Compliant
by Zacks Equity Research
NEOGEN (NEOG) completes organic certified water treatment program with the latest certification.
Syneos Health-Idorsia Collaborate to Launch Daridorexant in US
by Zacks Equity Research
Syneos Health (SYNH) inks deal with Idorsia to commercialize the treatment for insomnia in the United States.
Medtronic's (MDT) Cryoablation Suited for Patients With PAF
by Zacks Equity Research
Medtronic's (MDT) cryoablation therapy's superiority for the treatment of PAF over currently available AAD treatment gets reflected in trial results.
Medtronic (MDT) Sees Trend Rebound Amid Coronavirus Crisis
by Zacks Equity Research
Medtronic's (MDT) procedure volumes start to recover in multiple markets globally.
Hologic Updates Breast Biopsy System to Enhance Workflow
by Zacks Equity Research
Hologic (HOLX) introduces features to update Brevera Breast Biopsy System in order to transform patient experience and enhance workflow.
Tandem Diabetes' Advanced Insulin Pump Study Results Favorable
by Zacks Equity Research
Per the DCLP5 study, Tandem Diabetes' (TNDM) insulin pump with Control-IQ technology suitable for use in children aged six to 13 years, which has been published in the NEJM.
Bruker Rides on MALDI Launches Amid Coronavirus-Led Crisis
by Zacks Equity Research
For higher specific detection of the SARS-CoV-2 virus, Bruker (BRKR) launches luoroType SARS-CoV-2 plus next-generation 6-plex PCR assay.
ACADIA Acquires CerSci Therapeutics to Boost Pain Portfolio
by Zacks Equity Research
ACADIA (ACAD) purchases CerSci Therapeutics and in turn, secures the global rights to a suite of novel compounds for neurological disorders comprising non-opioid therapies for acute and chronic pain.
Hologic's Acessa Health Buyout to Broaden GYN Surgical Line
by Zacks Equity Research
Hologic's (HOLX) newly-acquired product line is set to complement its market-leading MyoSure products for hysteroscopic removal of fibroids.
Align Technology (ALGN) Strong on Robust Customer Adoption
by Zacks Equity Research
Align Technology (ALGN) treats the one millionth patient from the APAC region, highlighting the Invisalign system's continued adoption.
Bristol Myers to Buy Forbius to Boost Immunotherapy Pipeline
by Zacks Equity Research
Bristol Myers (BMY) enters into an agreement to acquire privately-held Forbius in a bid to boost its pipeline of immunotherapies.
Insulet (PODD) Banks on Omnipod Uptake Amid Coronavirus Woes
by Zacks Equity Research
Insulet (PODD) adds significant capacity in preparation for the Omnipod 5 launch in 2021.
Amedisys & BrightStar Ink Agreement to Expand Personal Care
by Zacks Equity Research
Amedisys (AMED) strengthens Personal Care business reach by entering into an agreement with BrightStar.
QIAGEN (QGEN) to Launch COVID-19 Antibody Test in the US
by Zacks Equity Research
QIAGEN's (QGEN) latest antibody test complements its array of COVID-19 testing solutions in an economical way to detect immune responses in people who have been exposed to the SARS-CoV-2 virus.